Evaluating a New International Risk-Prediction Tool in IgA Nephropathy | Zendy

Sean J. Barbour | Zendy; Rosanna Coppo | Zendy; Hong Zhang | Zendy; Zhihong Liu | Zendy; Yusuke Suzuki | Zendy; Keiichi Matsuzaki | Zendy; Ritsuko Katafuchi | Zendy; Lee Er | Zendy; Gabriela Espino-Hernández | Zendy; S. Joseph Kim | Zendy; Heather N. Reich | Zendy; John Feehally | Zendy; Daniel Cattran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy

Author(s) -

Sean J. Barbour,

Rosanna Coppo,

Hong Zhang,

Zhihong Liu,

Yusuke Suzuki,

Keiichi Matsuzaki,

Ritsuko Katafuchi,

Lee Er,

Gabriela Espino-Hernández,

S. Joseph Kim,

Heather N. Reich,

John Feehally,

Daniel Cattran

Publication year - 2019

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2019.0600

Subject(s) - medicine , interquartile range , nephropathy , renal function , kidney disease , proteinuria , cohort , proportional hazards model , oncology , kidney , endocrinology , diabetes mellitus

Although IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is no validated tool to predict disease progression. This limits patient-specific risk stratification and treatment decisions, clinical trial recruitment, and biomarker validation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research